Compare QCOM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCOM | SNY |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4B | 119.4B |
| IPO Year | 2009 | N/A |
| Metric | QCOM | SNY |
|---|---|---|
| Price | $146.35 | $47.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | ★ $170.89 | $61.50 |
| AVG Volume (30 Days) | ★ 10.0M | 4.4M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | 2.44% | ★ 3.36% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $44,284,000,000.00 | N/A |
| Revenue This Year | $0.90 | $2.62 |
| Revenue Next Year | $0.77 | $6.38 |
| P/E Ratio | $52.48 | ★ $6.14 |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $120.80 | $44.62 |
| 52 Week High | $205.55 | $60.12 |
| Indicator | QCOM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 50.58 |
| Support Level | $142.94 | $47.30 |
| Resistance Level | $149.30 | $49.28 |
| Average True Range (ATR) | 3.49 | 0.72 |
| MACD | 1.54 | 0.05 |
| Stochastic Oscillator | 96.26 | 45.53 |
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.